PA
ARQT icon

Perceptive Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Perceptive Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-300,000
Closed -$2.62M – 106
2023
Q3 		$2.62M Hold
300,000
– – 0.09% 80
2023
Q2 		$1.42M Buy
+300,000
New +$3.33M 0.04% 84

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Perceptive Advisors's ARQT Position: Q4 2024 in Review

Perceptive Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 1,358,500 shares — an estimated $12.6M sold.

Perceptive Advisors first reported a position in ARQT in Q1 2024 and held it in 3 quarters. The position peaked at $14.5M in Q2 2024. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • Perceptive Advisors reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Perceptive Advisors sold 1,358,500 Arcutis Biotherapeutics shares in Q4 2024, an estimated $12.6M.
  • Perceptive Advisors first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 3 quarters.
  • Perceptive Advisors's Arcutis Biotherapeutics position peaked at $14.5M in Q2 2024.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.